Every word of this outstanding editorial.

Bravo @pippa-matt.bsky.social @suwang88.bsky.social

And @lancetgastrohep.bsky.social

#LivSky #HepSky

Question for #LivSky #TLM24: Looking at abstract 5025 testing imdusiran & VTP-300 with or without nivolumab for non-cirrhotic hepatitis B. Given that well-tolerated generic antivirals can keep HBV suppressed indefinitely, why would you subject pts to cost & adverse events of a checkpoint inhibitor?

I think it is #livsky